FDA Rejects Moderna’s mRNA Flu Vaccine Application Amidst Shifting Agency Priorities
A controversial decision by the Food and Drug Administration to refuse review of Moderna’s first mRNA-based flu shot application has ignited concerns about the agency’s evolving standards and the influence of political appointees.
The FDA’s move, announced Tuesday, comes as the agency undergoes a period of internal reconsideration regarding vaccine approval procedures, particularly for influenza. These proposed changes stem from federal policy shifts initiated under President Donald Trump and have prompted widespread alarm among public health and medical experts.
Trial Design Questioned, No Safety Concerns Raised
According to a letter from the agency’s top vaccine regulator, Vinay Prasad, Moderna’s clinical trial was deemed not “adequate and well-controlled.” The FDA argued that the trial did not compare the experimental shot against the current leading product available on the market. In the trial, Moderna had evaluated its new vaccine against Fluarix, an existing influenza vaccine manufactured by GSK.
However, Moderna strongly disputes the FDA’s assessment, stating the rejection was “inconsistent with previous written communications” with the Center for Biologics Evaluation and Research (CBER), the FDA branch responsible for regulating vaccines. A company release emphasized that the decision “did not identify any safety or efficacy concerns with our product” and hinders “America’s leadership in developing innovative medicines.”
“It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting,” stated Moderna CEO Stephane Bancel.
The FDA issued a Refusal-to-File letter, indicating the application did not meet the minimum requirements for a substantive review. Moderna has requested a meeting with the agency to discuss the decision. Notably, the mRNA vaccine has been accepted for review in the European Union, Canada, and Australia.
From “Modern-Day Miracle” to Political Scrutiny
The rejection marks a significant turn for mRNA technology, initially hailed by President Trump during his first term as a “modern-day miracle.” This innovative technology proved crucial during the COVID-19 pandemic, enabling the rapid development of vaccines credited with saving millions of lives. Global health authorities continue to affirm the safety and effectiveness of COVID-19 vaccines.
However, the landscape shifted with President Trump’s second term and the appointment of Robert F. Kennedy Jr. as his health chief. Kennedy, a long-time and vocal vaccine skeptic, has spent the past year reshaping federal health agencies, promoting misinformation, and casting doubt on the safety and efficacy of established vaccines.
One significant action taken by Kennedy was the termination of federal research grants that previously funded mRNA development. This decision raises questions about the administration’s commitment to supporting cutting-edge medical research and its potential impact on future pandemic preparedness.
The FDA’s decision regarding Moderna’s flu vaccine application is the latest development in a growing trend of policy changes that are raising concerns about the politicization of public health and the potential erosion of scientific integrity.
